In addition, ablation of Crk by CRISPR/Cas9 inhibited in vivo growth of breast cancer cells (41), and ablation of both Crk and CrkL by CRISPR/Cas9 inhibited colorectal cancer cell adhesion, migration, invasion, and proliferation (42). Here, CRKL is linked to breast carcinoma.